AU2018207564A1 - Compositions and methods for treating farber disease - Google Patents

Compositions and methods for treating farber disease Download PDF

Info

Publication number
AU2018207564A1
AU2018207564A1 AU2018207564A AU2018207564A AU2018207564A1 AU 2018207564 A1 AU2018207564 A1 AU 2018207564A1 AU 2018207564 A AU2018207564 A AU 2018207564A AU 2018207564 A AU2018207564 A AU 2018207564A AU 2018207564 A1 AU2018207564 A1 AU 2018207564A1
Authority
AU
Australia
Prior art keywords
pct
rhac
subject
leu
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018207564A
Other languages
English (en)
Inventor
Edward H. Schuchman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Icahn School of Medicine at Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School of Medicine at Mount Sinai filed Critical Icahn School of Medicine at Mount Sinai
Publication of AU2018207564A1 publication Critical patent/AU2018207564A1/en
Priority to AU2025200254A priority Critical patent/AU2025200254A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01023—Ceramidase (3.5.1.23)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2018207564A 2017-01-13 2018-01-12 Compositions and methods for treating farber disease Abandoned AU2018207564A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025200254A AU2025200254A1 (en) 2017-01-13 2025-01-14 Compositions and methods for treating farber disease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762446166P 2017-01-13 2017-01-13
US62/446,166 2017-01-13
PCT/US2018/013509 WO2018132667A1 (en) 2017-01-13 2018-01-12 Compositions and methods for treating farber disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025200254A Division AU2025200254A1 (en) 2017-01-13 2025-01-14 Compositions and methods for treating farber disease

Publications (1)

Publication Number Publication Date
AU2018207564A1 true AU2018207564A1 (en) 2019-08-08

Family

ID=62839661

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018207564A Abandoned AU2018207564A1 (en) 2017-01-13 2018-01-12 Compositions and methods for treating farber disease
AU2025200254A Pending AU2025200254A1 (en) 2017-01-13 2025-01-14 Compositions and methods for treating farber disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025200254A Pending AU2025200254A1 (en) 2017-01-13 2025-01-14 Compositions and methods for treating farber disease

Country Status (8)

Country Link
US (4) US20190343936A1 (enExample)
EP (2) EP4295903A3 (enExample)
JP (3) JP7576293B2 (enExample)
AU (2) AU2018207564A1 (enExample)
CA (1) CA3049771A1 (enExample)
JO (1) JOP20190164B1 (enExample)
MX (1) MX2019008038A (enExample)
WO (1) WO2018132667A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7576293B2 (ja) * 2017-01-13 2024-10-31 アイカーン スクール オブ メディシン アット マウント サイナイ ファーバー病を治療するための組成物及び方法
EP3648776A4 (en) * 2017-07-06 2021-04-07 The Medical College of Wisconsin, Inc. NEW IN-VITRO AND IN-VIVO ENRICHMENT STRATEGY AGAINST LYMPHOCYTE FROM VECTOR-TRANSDUCED HSC FOR THE TREATMENT OF DISEASES
MX2020007501A (es) * 2018-02-02 2020-10-16 Enzyvant Therapeutics Gmbh Metodos para tratar la enfermedad de farber.
EP3784695B1 (en) 2018-04-27 2023-08-09 The Medical College of Wisconsin, Inc. Use of lentivector-transduced t-rapa cells for amelioration of lysosomal storage disorders
WO2020152532A1 (en) 2019-01-23 2020-07-30 Enzyvant Therapeutics Gmbh Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2854910T (lt) * 2012-06-01 2020-05-25 Icahn School Of Medicine At Mount Sinai Ceramido lygiai infekcijos gydymo ir prevencijos metu
WO2014160390A1 (en) * 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them
JP7576293B2 (ja) * 2017-01-13 2024-10-31 アイカーン スクール オブ メディシン アット マウント サイナイ ファーバー病を治療するための組成物及び方法
WO2019060837A1 (en) * 2017-09-25 2019-03-28 Enzyvant Farber Gmbh PROCESS FOR PRODUCING RECOMBINANT HUMAN ACID CERAMIDASE
MX2020007501A (es) * 2018-02-02 2020-10-16 Enzyvant Therapeutics Gmbh Metodos para tratar la enfermedad de farber.

Also Published As

Publication number Publication date
JOP20190164A1 (ar) 2019-07-02
US20240075113A1 (en) 2024-03-07
JP2023011938A (ja) 2023-01-24
EP3568154B1 (en) 2023-07-12
JP2020514305A (ja) 2020-05-21
US20220313800A1 (en) 2022-10-06
EP4295903A3 (en) 2024-03-27
MX2019008038A (es) 2020-02-05
EP4295903A2 (en) 2023-12-27
WO2018132667A1 (en) 2018-07-19
US20250170225A1 (en) 2025-05-29
CA3049771A1 (en) 2018-07-19
US20190343936A1 (en) 2019-11-14
JP7576293B2 (ja) 2024-10-31
EP3568154A4 (en) 2020-11-18
AU2025200254A1 (en) 2025-01-30
JP2024169509A (ja) 2024-12-05
EP3568154A1 (en) 2019-11-20
JOP20190164B1 (ar) 2023-09-17

Similar Documents

Publication Publication Date Title
US20220313800A1 (en) Compositions and methods for treating farber disease
JP7390349B2 (ja) 病的石灰化状態を治療するための組成物およびそれを使用する方法
He et al. Enzyme replacement therapy for Farber disease: Proof-of-concept studies in cells and mice
JP2020523035A (ja) タウ凝集阻害剤
JP2025041867A (ja) ファーバー病を処置するための方法
HK40105998A (en) Compositions and methods for treating farber disease
JP2023159164A (ja) ファーバー病マーカーおよびその使用
US20220088158A1 (en) Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase
US20260000741A1 (en) Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase
DE60120131T2 (de) Antiangiogene Eigenschaften von Vascostatin und Fragmenten und Varianten davon
US20210199670A1 (en) Farber disease markers and uses thereof
WO2022272180A2 (en) Mmp-14 antibodies and uses thereof

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted